MorphoSys AG : to Host Conference Call on Clinical Trial Results of MOR103 in Rheumatoid Arthritis
09/21/2012| 01:35am US/Eastern
MorphoSys AG /
MorphoSys to Host Conference Call on Clinical Trial Results of MOR103 in
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Today at 3:00 p.m. CET (2:00 p.m. BST, 9:00 a.m. EDT), the Management Board of MorphoSys AG will host a public conference call and webcast to present information on the results of the clinical phase 1b/2a trial of MorphoSys's proprietary antibody MOR103 in patients with rheumatoid arthritis, which was announced yesterday.
Dial-in numbers for the Conference Call (listen-only):
Germany: +49 (0) 89 2444 32975
For U.K. residents: +44 (0) 20 3003 2666
For U.S. residents: +1 202 204 1514
MorphoSys offers participants the opportunity to follow the presentation through a simultaneous slide presentation online at http://www.morphosys.com:
An audio replay and manuscripts of the conference will be available on www.morphosys.com/conference-calls:
http://www.morphosys.com/conference-calls in due course.
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. The Company's AbD Serotec:
http://www.abd-serotec.com/ unit uses HuCAL and other technologies to generate superior monoclonal antibodies for research and diagnostic applications.
Through its own development efforts and successful partnerships in the pharmaceutical industry, MorphoSys has built a therapeutic pipeline:
http://www.morphosys.com/pipeline of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on engineering the medicines of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com:
MOR103 is a fully human antibody against GM-CSF (granulocyte macrophage-colony stimulating factor). GM-CSF was originally identified as a growth factor for granulocytes and macrophages but has more recently been identified as an inflammatory mediator in autoimmune disorders such as RA. GM-CSF stimulates stem cells to produce granulocytes and other macrophages and subsequently activates these differentiated immune cells leading to an increased production of pro-inflammatory cytokines, chemokines and proteases and thereby ultimately to articular destruction. The antibody MOR103 blocks GM-CSF and reduces its pro-inflammatory activity.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia® and 100 billion high potentials® are registered trademarks of MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
For more information, please contact:
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
Conference Call Alert:
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE